{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05180162",
            "orgStudyIdInfo": {
                "id": "20-32872"
            },
            "organization": {
                "fullName": "University of California, San Francisco",
                "class": "OTHER"
            },
            "briefTitle": "Imaging of Pathologic Fibrosis Using 68Ga-FAP-2286",
            "officialTitle": "Imaging of Pathologic Fibrosis Using 68Ga-FAP-2286",
            "therapeuticArea": [
                "Respiratory",
                "Other",
                "Gastroenterology"
            ],
            "study": "imaging-of-pathologic-fibrosis-using-fap"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-03",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2021-12-09",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-12-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-12-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-12-17",
            "studyFirstSubmitQcDate": "2022-01-05",
            "studyFirstPostDateStruct": {
                "date": "2022-01-06",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-03-07",
            "lastUpdatePostDateStruct": {
                "date": "2024-03-12",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR_INVESTIGATOR",
                "investigatorFullName": "Thomas Hope",
                "investigatorTitle": "Principal Investigator",
                "investigatorAffiliation": "University of California, San Francisco"
            },
            "leadSponsor": {
                "name": "Thomas Hope",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "Clovis Oncology, Inc.",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is a single arm prospective pilot trial that evaluates the ability of a novel imaging agent (68Ga-FAP-2286) to identify pathologic fibrosis in the setting of hepatic, cardiac and pulmonary fibrosis.\n\nFAP-2286 is a peptide that potently and selectively binds to Fibroblast Activation Protein (FAP). FAP is a transmembrane protein expressed on fibroblasts and has been shown to have higher expression in idiopathic pulmonary fibrosis (IPF), cirrhosis, and cardiac fibrosis.",
            "detailedDescription": "PRIMARY OBJECTIVES:\n\nI. All cohorts: Safety of 68Ga-FAP-2286.\n\nII. Cohort 1: Measured uptake of radiotracer (SUVpeak) in regions of known liver fibrosis.\n\nIII. Cohort 2: Measured uptake of radiotracer (SUVpeak) in regions of known pulmonary fibrosis.\n\nIV. Cohort 3: Measured uptake of radiotracer (SUVpeak) in regions of myocardial fibrosis.\n\nEXPLORATORY OBJECTIVES:\n\nI. Correlation of 68Ga-FAP-2286 uptake with FAP expression determined by immunohistochemistry.\n\nII. Compare 68Ga-FAP-2286 scan results to archival Computerized tomography (CT), magnetic resonance imaging (MRI), or Positron Emission Tomography (PET) images.\n\nPatients will receive a single administration of 68Ga-FAP-2286 prior to PET imaging and will be followed for up to two hours after the injection of 68Ga-FAP-2286 for evaluation of adverse events."
        },
        "conditionsModule": {
            "conditions": [
                "Liver Fibrosis",
                "Pulmonary Fibrosis",
                "Myocardial Fibrosis"
            ],
            "keywords": [
                "Positron Emission Tomography (PET)",
                "Imaging",
                "68Ga-FAP-2286"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "DIAGNOSTIC",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 30,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Cohort 1: Liver Fibrosis",
                    "type": "EXPERIMENTAL",
                    "description": "Patients with liver fibrosis will receive a single administration of 68Ga-FAP-2286 prior to PET imaging.",
                    "interventionNames": [
                        "Drug: 68Ga-FAP-2286",
                        "Procedure: Positron Emission Tomography (PET)"
                    ]
                },
                {
                    "label": "Cohort 2: Pulmonary Fibrosis",
                    "type": "EXPERIMENTAL",
                    "description": "Patients with pulmonary fibrosis will receive a single administration of 68Ga-FAP-2286 prior to PET imaging.",
                    "interventionNames": [
                        "Drug: 68Ga-FAP-2286",
                        "Procedure: Positron Emission Tomography (PET)"
                    ]
                },
                {
                    "label": "Cohort 3: Myocardial Fibrosis",
                    "type": "EXPERIMENTAL",
                    "description": "Patients with myocardial fibrosis will receive a single administration of 68Ga-FAP-2286 prior to PET imaging.",
                    "interventionNames": [
                        "Drug: 68Ga-FAP-2286",
                        "Procedure: Positron Emission Tomography (PET)"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "68Ga-FAP-2286",
                    "description": "A dose of 3 - 8 millicurie (mCi) will be given intravenously (IV)",
                    "armGroupLabels": [
                        "Cohort 1: Liver Fibrosis",
                        "Cohort 2: Pulmonary Fibrosis",
                        "Cohort 3: Myocardial Fibrosis"
                    ],
                    "otherNames": [
                        "68Gallium-Fibroblast Activation Protein-2286"
                    ]
                },
                {
                    "type": "PROCEDURE",
                    "name": "Positron Emission Tomography (PET)",
                    "description": "Imaging will begin 50-100 minutes after injection and last about 45 minutes.",
                    "armGroupLabels": [
                        "Cohort 1: Liver Fibrosis",
                        "Cohort 2: Pulmonary Fibrosis",
                        "Cohort 3: Myocardial Fibrosis"
                    ],
                    "otherNames": [
                        "PET Imaging",
                        "PET Scan"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Proportion of participants with treatment-related adverse events",
                    "description": "Proportion of participants with Adverse Events, as graded by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0 will be reported.",
                    "timeFrame": "Up to 31 days"
                },
                {
                    "measure": "Median peak standardized uptake value (SUVpeak) in liver region",
                    "description": "The median SUVpeak in regions of known liver fibrosis will be reported with 95% confidence intervals",
                    "timeFrame": "Up to 1 days"
                },
                {
                    "measure": "Median peak standardized uptake value (SUVpeak) in lung region",
                    "description": "The median SUVpeak in regions of known pulmonary fibrosis will be reported with 95% confidence intervals",
                    "timeFrame": "Up to 1 days"
                },
                {
                    "measure": "Median peak standardized uptake value (SUV) in myocardium region",
                    "description": "The median SUVpeak in regions of known myocardial fibrosis will be reported with 95% confidence intervals",
                    "timeFrame": "Up to 1 days"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. Age \\>= 18 years.\n2. Confirmed pathologic fibrosis in one of the following cohorts\n\n   1. Cohort 1: Hepatic fibrosis, based on cirrhosis on imaging or hepatic fibrosis on liver biopsy.\n   2. Cohort 2: Pulmonary fibrosis, based on CT findings or biopsy of lung parenchyma.\n   3. Cohort 3: High likelihood of cardiac fibrosis as indicated by known cardiac sarcoidosis or amyloidosis (shown on MRI or Fluorodeoxyglucose (FDG) PET), recent myocardial infarction within the last 30 days (as shown by an elevated troponin), known cardiotoxicity (decreased ejection fraction on systemic therapy), or other known inflammatory or infiltrative disease.\n3. Ability to understand a written informed consent document, and the willingness to sign it.\n\nExclusion Criteria:\n\n1. Unlikely to comply with protocol procedures, restrictions and requirements and judged by the Investigator to be unsuitable for participation.\n2. Known pregnancy.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Brad Kline",
                    "role": "CONTACT",
                    "phone": "877-827-3222",
                    "email": "Brad.Kline@ucsf.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Thomas A Hope, MD",
                    "affiliation": "University of California, San Francisco",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "University of California, San Francisco",
                    "status": "RECRUITING",
                    "city": "San Francisco",
                    "state": "California",
                    "zip": "94122",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Brad Kline",
                            "role": "CONTACT",
                            "phone": "877-827-3222",
                            "email": "Brad.Kline@ucsf.edu"
                        },
                        {
                            "name": "Thomas A Hope, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.77493,
                        "lon": -122.41942
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000008103",
                    "term": "Liver Cirrhosis"
                },
                {
                    "id": "D000011658",
                    "term": "Pulmonary Fibrosis"
                },
                {
                    "id": "D000005355",
                    "term": "Fibrosis"
                }
            ],
            "ancestors": [
                {
                    "id": "D000010335",
                    "term": "Pathologic Processes"
                },
                {
                    "id": "D000017563",
                    "term": "Lung Diseases, Interstitial"
                },
                {
                    "id": "D000008171",
                    "term": "Lung Diseases"
                },
                {
                    "id": "D000012140",
                    "term": "Respiratory Tract Diseases"
                },
                {
                    "id": "D000008107",
                    "term": "Liver Diseases"
                },
                {
                    "id": "D000004066",
                    "term": "Digestive System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M14512",
                    "name": "Pulmonary Fibrosis",
                    "asFound": "Pulmonary Fibrosis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M8485",
                    "name": "Fibrosis",
                    "asFound": "Fibrosis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11103",
                    "name": "Liver Cirrhosis",
                    "asFound": "Liver Fibrosis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11168",
                    "name": "Lung Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M19813",
                    "name": "Lung Diseases, Interstitial",
                    "relevance": "LOW"
                },
                {
                    "id": "M14977",
                    "name": "Respiratory Tract Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M11107",
                    "name": "Liver Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M7255",
                    "name": "Digestive System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8883",
                    "name": "Gastrointestinal Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC08",
                    "name": "Respiratory Tract (Lung and Bronchial) Diseases"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC06",
                    "name": "Digestive System Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M11110",
                    "name": "Liver Extracts",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Hemat",
                    "name": "Hematinics"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}